Login / Signup

A Comparison of Sodium-Glucose Co-Transporter 2 Inhibitor Kidney Outcome Trial Participants with a Real-World Chronic Kidney Disease Primary Care Population.

Anna K ForbesWilliam HintonMichael D FeherWilliam ElsonJosé M Ordóñez-MenaMark JoyXuejuan FanDebasish BanerjeeNicholas I ColeNeil MunroMartin WhyteRebecca J SucklingPauline A SwiftSimon de Lusignan
Published in: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2024)
SGLT2 inhibitor kidney outcome trials represent a sub-group of people with CKD at high risk of adverse kidney events. Out study highlights the importance of complementing trials with real-world studies, exploring the effectiveness of SGLT2 inhibitors in the broader population of people with CKD.
Keyphrases
  • chronic kidney disease
  • end stage renal disease
  • primary care
  • randomized controlled trial
  • systematic review
  • clinical trial
  • study protocol
  • phase iii
  • phase ii
  • open label
  • adverse drug